Researchers reviewed the phase 3 findings of a TKI inhibitor treatment compared with aflibercept 2 mg for maintaining vision in patients with wet AMD.
Capricor plans to resubmit its BLA to the FDA, incorporating data from the ongoing Phase 3 HOPE-3 trial, indicating proactive steps toward potential approval for Deramiocel. The FDA's invitation for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results